Aligos Therapeutics Inc ALGS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 6,190,000 |
| Website | aligos.com/ ↗ |
| Phone | 13026587581 |
| Employees | 82 |
| Revenue | $2.8M |
| Gross Profit | $2.8M |
| Net Income | -$23.0M |
| Free Cash Flow | -$85.2M |
| Total Assets | $64.6M |
| Total Liabilities | $32.8M |
| Equity | $31.8M |
About Aligos Therapeutics Inc
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Aligos Therapeutics Inc is a publicly traded company under the ticker symbol ALGS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)